Cancerworld Magazine
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
NEWSLETTER  |  PRINT VERSION
Facebook
Twitter
LinkedIn
Cancerworld Magazine
Cancerworld Magazine
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
Cancerworld Magazine > News > Dexamethasone helps cancer patients with non-immunogenic tumours survive longer after surgery
  • News

Dexamethasone helps cancer patients with non-immunogenic tumours survive longer after surgery

  • 14 October 2021
  • Janet Fricker
Dexamethasone helps cancer patients with non-immunogenic tumours survive longer after surgery
Total
0
Shares
0
0
0
0
0

Patients with non-immunogenic cancers, such as breast and gynaecological cancers, who are given the anti-nausea drug dexamethasone during surgery survive longer. The study, abstract 4224, presented at the Anesthesiology 2021 annual meeting, held October 8 to 12, San Diego, found that the risk of dying within 90 days after cancer surgery was 32% lower in patients who received dexamethasone compared to those not receiving the drug.

“Based on our data, physician anaesthesiologists should feel more confident in administering dexamethasone to patients undergoing surgery for cancers that have little interaction with the immune system,” said study senior author Maximilian Schaefer, from Beth Israel Deaconess Medical Center and Harvard Medical School, Boston. “It does not only prevent nausea, but may also improve survival.”

At the beginning of surgery dexamethasone is administered as a prophylactic medication (single bolus intravenously) to prevent postoperative nausea and/ or vomiting. Whether or not dexamethasone is used is at the discretion of anaesthesiologists.

Dexamethasone, a glucocorticoid available since 1958, is known to dampen the immune system. Studies have also suggested that dexamethasone can prevent cancer growth via direct effects on the tumour. However, previous clinical studies have produced conflicting results, with some reporting higher survival and others lower survival after dexamethasone use.

The explanation for these differing effects, Schaefer hypothesized, is that in cancers where the immune system suppresses growth, inhibiting the immune system with dexamethasone would have a negative effect on tumour control, cancelling out the positive effect. However, in non-immunogenic cancers, direct effect on the cancer would go unhindered.

For the current study, Schaefer and his team analysed the records of 74,058 patients who underwent surgery to remove non-immunogenic cancers at Beth Israel Deaconess Medical Center (between 2005 and 2020) and Massachusetts General Hospital Boston (between 2007 and 2015).

Overall, 25,178 (34%) received dexamethasone during surgery. After 90 days, 209 (0.83%) of patients who had received dexamethasone died compared with 1,543 (3.2%) who had not received the drug. When statistical modelling took into account confounders (such as patient demographics, comorbidities, intraoperative factors, preoperative steroid use and chemotherapy) preoperative dexamethasone administration was associated with decreased risk of 90-day mortality with an adjusted odds ratio (aOR) of 0.68 (95% CI 0.57-0.81; p<0.001).

Subgroup analyses showed that dexamethasone was particularly beneficial for patients with breast cancer (aOR=0.22; 95% CI 0.11-0.45; p<0.001), and gynaecological malignancies (ovary, uterus, cervix), (aOR=0.33; 95% CI 0.16-0.66; p=0.002).

“Ours is the first large study to show that for a wide variety of cancers where the immune system does not play a major role, the positive effects seem to predominate,” said Schaefer. The next step, he added, will be to verify the results for dexamethasone in larger national datasets and also explore the effects of different anti-inflammatory drugs administered during surgery for cancer.

Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Related Topics
  • anti-inflammatory drugs
  • cancer surgery
  • cancer survivors
  • dexamethasone
  • non-immunogenic cancers
Janet Fricker

Previous Article
  • Voices

When your patient tells you they’re still not better, please accept what they say

  • 14 October 2021
  • Cordelia Galgut
View Post
Next Article
  • News

What’s new in lung and colorectal cancer? reports from ESMO 2021

  • 15 October 2021
  • Janet Fricker
View Post
You May Also Like
View Post
  • News

Multicomponent prevention strategy reduces risk of cancer

  • Janet Fricker
  • 20 May 2022
View Post
  • News

Lumpectomy as effective as mastectomy in young breast cancer patients

  • Janet Fricker
  • 13 May 2022
View Post
  • News

Multi organ chip could facilitate personalised cancer therapy 

  • Janet Fricker
  • 12 May 2022
View Post
  • News

100,000 Genomes Project pinpoints new cancer genetic culprits

  • Janet Fricker
  • 29 April 2022
View Post
  • News

IL-6 provides missing link between exercise and colon cancer protection

  • Janet Fricker
  • 28 April 2022
View Post
  • News

CAR T-cell therapy shows efficacy in solid tumours

  • Janet Fricker
  • 20 April 2022
View Post
  • News

No link between brain tumours and ‘usual’ use of mobile phones

  • Janet Fricker
  • 14 April 2022
View Post
  • News

Radiologists urged to report breast arterial calcification for CVD prevention

  • Janet Fricker
  • 30 March 2022

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

search
or search in Cancerworld archive
Newsletter

Subscribe free to
Cancerworld!

We'll keep you informed of the latest features and news with a fortnightly email

Subscribe now
Latest News
  • Multicomponent prevention strategy reduces risk of cancer
    • 20 May 2022
  • Lumpectomy as effective as mastectomy in young breast cancer patients
    • 13 May 2022
  • Multi organ chip could facilitate personalised cancer therapy 
    • 12 May 2022
  • 100,000 Genomes Project pinpoints new cancer genetic culprits
    • 29 April 2022
  • IL-6 provides missing link between exercise and colon cancer protection
    • 28 April 2022
Article
  • What can we expect from mRNA cancer vaccines?
    • 13 May 2022
  • Sri Lanka cancer care hit by foreign currency crisis
    • 6 May 2022
  • From social determinants to cancer outcomes: the cell biology behind the disparities
    • 29 April 2022
Latest printed issue
Social

Would you follow us ?

Contents
  • Message from a Ukrainian oncologist: Please prioritise my patients ‒ if you don’t who will?
    • 19 April 2022
  • Pandemics, War, Reconstruction and the Duty of Medicine and Science
    • 4 April 2022
  • Crisis in the Ukraine: we can help by doing what we do best
    • 4 March 2022
MENU
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
Cancerworld Magazine
  • About the Magazine
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy

Cancerworld is funded by SPCC Sharing Progress in Cancer Care | Piazza Indipendenza 2, 6500 Bellinzona - Switzerland | info@spcc.net

Archivio Cancerworld

Input your search keywords and press Enter.